The Panorama™ Prenatal Test

The unique methodology of the Panorama prenatal screening test utilizes single nucleotide polymorphism (SNP) technology and is much more efficient and accurate than the counting or quantitative methods used by all other available non-invasive prenatal tests.

How does Natera non-invasively examine fetal DNA?

This NATUS (Next-generation Aneuploidy Testing Using SNPs) methodology evaluates specific maternal and fetal DNA found in the mother’s blood. This allows the Panorama prenatal test to provide consistent sensitivity and specificity (identifying accurately there is an incorrect number of chromosomes) across all chromosomes, even at low fetal fractions. The result is a patient-specific personalized risk score, and a decreased chance of false positives or false negatives with a low no call rate.

While fetal fraction of DNA in the mother’s blood can vary greatly throughout gestation, it does tend to be lower earlier in the pregnancy. By using SNP technology, the Panorama prenatal test has strong detection rates even at lower fetal fractions and can be used as early as 9 weeks gestational age.

The Panorama prenatal test was developed by Natera, Inc., a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).

Share this Page

Why The Panorama Test?

The Panorama prenatal test provides superior coverage and the best detection and accuracy over any other current screening methods.

learn more

Proven by our Science

Clinical data proves the Panorama prenatal test identifies more chromosomal abnormalities than any other prenatal test, with higher accuracy than any other prenatal tests available.

view data results

We are social. Follow the Panorama Test:

  Follow Natera:

You are now leaving this website. If you would like to continue, click Continue.